Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment

A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid Tumors

The purpose of this study is to test the safety of neratinib at different dose levels and to find out what effects, good and bad, it has on the patients and the cancer.

Study Overview

• Status: Active, not recruiting
• Conditions: Lymphoma; Leukemia; Solid Tumor; Central Nervous System Tumor
• Intervention / Treatment: Drug: Neratinib

• Study Type: Interventional
• Enrollment (Actual): 14
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Canada
  • Alberta
    • Calgary, Alberta, Canada, T3B 6A8
      • Alberta Children's Hospital
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85016
      • Phoenix Children's Hospital
  • Arkansas
    • Little Rock, Arkansas, United States, 72206
      • Arkansas Children's Hospital
  • California
    • Palo Alto, California, United States, 94304
      • Stanford University School of Medicine and Stanford Cancer Institute
  • Florida
    • Orlando, Florida, United States, 32806
      • Arnold Palmer Hospital for Children
  • New York
    • New York, New York, United States, 10065
      • Memorial Sloan Kettering Cancer Center
  • Pennsylvania
    • Hershey, Pennsylvania, United States, 17033
      • Pennsylvania State Hershey Children's Hospital
  • Texas
    • San Antonio, Texas, United States, 78229
      • University of Texas
  • Utah
    • Salt Lake City, Utah, United States, 84113
      • Huntsman Cancer Institue

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years to 21 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosis: Pathologic confirmation of solid tumor, including central nervous system tumor or lymphoma.
• Recurrent or Refractory Disease for which no further effective standard treatment is available.
• Patient must have failed at least one prior therapy.

• All patients must have evaluable disease as defined as:

  • Solid tumors must have a lesion evaluable by RECIST criteria version 1.1;
  • Central nervous system tumors will be evaluated by RANO criteria.
• Available tissue to perform protein and genomic analysis

• Age:

  • Phase 1: ≥ 3 and ≤ 21 years of age at time of enrollment
  • Phase 2: ≥ 3 and ≤ 21 years of age at diagnosis
• Body Surface Area requirements varied by dose level:

Dose Level BSA (m2)

• 1 ≥ 0.82

  1. ≥ 0.66
  2. ≥ 0.52
  3. ≥ 0.45

• Performance level:

  • Lansky score ≥ 60% (patients < 16 years of age)
  • Karnofsky score ≥ 60% (patients ≥ 16 years of age)
• Cardiac Function: Patients must have a shortening fraction ≥ 27% or left ventricular ejection fraction ≥ 50% measured by echocardiogram (ECHO) or measured by multiple-gated acquisition scans (MUGA).
• Negative β-human chorionic gonadotropin (hCG) pregnancy test for female patients of child-bearing potential ≤ 7 days before starting neratinib therapy.
• Female patients of reproductive potential must agree and commit to the use of a highly effective method of contraception, as determined to be acceptable by the investigator, from the time of informed consent until 28 days after the last dose of the investigational product. Male patients must agree and commit to use a barrier method of contraception while on treatment and for 3 months after the last dose of the investigational product.
• Written informed consent/assent prior to any study-specific procedures.
• Patient must be able to swallow tablet or have existing gastrostomy feeding tube to enable administration of tablet.
• Patients must have recovered from the acute toxic effects of all prior therapy to ≤ grade 1 before entering this study.

Exclusion Criteria:

• Prior treatment within the following timeframes:

  • Systemic chemotherapy or biologic therapy ≤ 2 weeks or 5 half lives (t ½) of the agent used, whichever is shorter, prior to the start of neratinib
  • Radiation therapy outside the central nervous system ≤ 14 days prior to neratinib
  • Radiation to the central nervous system ≤ 12 weeks prior to initiation of neratinib

• Patients with previous allogeneic stem cell transplant (SCT) if they meet either of the following criteria:

  • 60 days from allogeneic SCT

    • Active acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment for GvHD

• Inadequate marrow function in Cohort 1:

  • Absolute neutrophil count < 1.0 x 10^9 /L
  • Platelets < 100 x 10^9 /L
  • Hemoglobin < 8.0 g/dL (transfusion permitted at least 7 days prior to baseline)
• Total bilirubin > 1.5 X the upper limit of normal (ULN) for age
• AST (SGOT) and ALT (SGPT) > 3 X ULN (unless attributed to disease involvement)
• Serum creatinine > 1.5 X ULN for age or creatinine clearance ≤ 60mL/min/1.73m^2
• Symptomatic or unstable brain metastases. (Note: Asymptomatic patients with metastatic brain disease who have been on a stable dose of corticosteroids for treatment of brain metastases for at least 14 days (or decreasing dose of corticosteroid) are eligible to participate in the study.) Patients with primary central nervous system tumors are eligible.
• Clinically active cardiac disease, including prolonged QTc interval ≥ 481ms (i.e. ≥ grade 2)
• Pregnant or breast-feeding women
• Being actively treated for a concurrent malignancy with the exception of basal cell carcinoma or carcinoma in situ of the cervix.
• Uncontrolled intercurrent illness including, but not limited to uncontrolled infection, unexplained fever > 38.5°C (101.3°F) or psychiatric illness/social situation that would limit compliance with study requirements.
• Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn's disease, malabsorption, or Grade ≥ 2 National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events Version 4.0 [CTCAE v.4.0] diarrhea of any etiology at baseline).
• Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related disease
• Known history of hepatitis C or known active hepatitis B infection
• Known hypersensitivity to any component of the investigational product

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Neratinib; There are 2 parts to this study: a Phase I part and a Phase II part. The Phase I portion is known as the dose escalation phase where neratinib will be tested in groups of 3-6 patients to establish the maximum tolerated dose (MTD). The phase II portion will determine whether the MTD shows a response to the tumor.	Drug: Neratinib; Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the number of patients who have experienced Dose Limiting Toxicity	NCI CTCAE Version 4.0.Definition of Hematologic Dose-Limiting Toxicity (solid tumor cohort only) Any hematologic toxicity as indicated: Febrile neutropenia defined as Grade 3 or 4 neutropenia with fever ≥ 38.5°C and /or infection requiring antibiotic or antifungal treatment Grade 4 neutropenia lasting > 7 days Grade 4 thrombocytopenia lasting > 7days Any drug-related adverse experience, regardless of grade, leading to a dose reduction of a study drug. Non-Hematologic Dose-Limiting Toxicities: Non-hematologic dose-limiting toxicity will be defined as any Grade 3, 4 or 5 nonhematologic toxicity with the specific exception of: Any grade diarrhea that occurs in the setting of poor compliance with supportive measures that last for < 48 hours Any grade dehydration related to diarrhea that occurs in the setting of inadequate compliance to supportive care measures that last for < 48 hours.	1 year

Collaborators and Investigators

• Sponsor: Memorial Sloan Kettering Cancer Center
• Collaborators: M.D. Anderson Cancer Center; Milton S. Hershey Medical Center; Stanford University; University of Texas; Alberta Children's Hospital; Phoenix Children's Hospital; Arkansas Children's Hospital Research Institute
• Investigators: Principal Investigator: Tanya Trippett, MD, Memorial Sloan Kettering Cancer Center

Publications and helpful links

Helpful Links

• Memorial Sloan Kettering Cancer Center

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2016
• Primary Completion (Estimated): October 1, 2026
• Study Completion (Estimated): October 1, 2026

Study Registration Dates

• First Submitted: October 12, 2016
• First Submitted That Met QC Criteria: October 12, 2016
• First Posted (Estimated): October 13, 2016

Study Record Updates

• Last Update Posted (Estimated): December 5, 2025
• Last Update Submitted That Met QC Criteria: December 3, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Neratinib; Recurrent; Refractory Disease; 16-878
• Additional Relevant MeSH Terms: Nervous System Diseases; Pathologic Processes; Neoplasms by Site; Neoplasms; Disease Attributes; Immune System Diseases; Neoplasms by Histologic Type; Hematologic Diseases; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Nervous System Neoplasms; Pathological Conditions, Signs and Symptoms; Hemic and Lymphatic Diseases; Recurrence; Leukemia; Disease; Lymphoma; Central Nervous System Neoplasms; Tyrosine Kinase Inhibitors; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protein Kinase Inhibitors; neratinib
• Other Study ID Numbers: 16-878